MDGL Q1 2021 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$53M

Net Income

-$53M

EPS (Diluted)

$-3.32

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$43M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$310M

Total Liabilities

$49M

Stockholders' Equity

$261M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$53M	-$38M	-39.4%
Net Income	-$53M	-$36M	-45.4%